The Evolving Policy Landscape: U.S. And EU Pricing And Access

Regulatory shifts on both sides of the Atlantic are creating real pressure on how manufacturers plan launches, sequence markets, and build evidence strategies. The U.S. Inflation Reduction Act, Most Favored Nation pricing, and 340B program changes are converging with the EU's new Joint Clinical Assessment requirements and the proposed Biotech Act, making it harder to anticipate the rules of engagement even 12 months out. If your organization is navigating pricing negotiations, access planning, or compliance timelines, understanding these developments early is critical.

This webinar brings together leading experts to decode the most consequential 2025-2026 policy developments across U.S. and EU markets, with a focus on practical implications for manufacturer strategy. You will come away with a clearer picture of how pricing dynamics are shifting, what the new EU HTA framework means for evidence generation and submission planning, and where manufacturers are most exposed to compliance risk.

Rather than a policy overview in the abstract, the discussion is grounded in what these changes mean for decisions you are making now about launch sequencing, payer engagement, and long-term access strategy. Watch the session below to get the expert perspective on planning confidently in an unpredictable policy environment.